JP2009516747A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009516747A5 JP2009516747A5 JP2008542425A JP2008542425A JP2009516747A5 JP 2009516747 A5 JP2009516747 A5 JP 2009516747A5 JP 2008542425 A JP2008542425 A JP 2008542425A JP 2008542425 A JP2008542425 A JP 2008542425A JP 2009516747 A5 JP2009516747 A5 JP 2009516747A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- independently
- carbocyclyl
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 43
- XRMDCWJNPDVAFI-UHFFFAOYSA-N 2,2,6,6-tetramethyl-1-oxopiperidin-1-ium-4-ol Chemical compound CC1(C)CC(O)CC(C)(C)[N+]1=O XRMDCWJNPDVAFI-UHFFFAOYSA-N 0.000 claims 40
- 125000000217 alkyl group Chemical group 0.000 claims 39
- 229910052799 carbon Inorganic materials 0.000 claims 37
- 125000000623 heterocyclic group Chemical group 0.000 claims 35
- 125000004452 carbocyclyl group Chemical group 0.000 claims 33
- -1 hydantoinyl Chemical group 0.000 claims 29
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 125000005884 carbocyclylalkyl group Chemical group 0.000 claims 16
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 16
- 125000002947 alkylene group Chemical group 0.000 claims 14
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 12
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- 229910052801 chlorine Inorganic materials 0.000 claims 10
- 229910052731 fluorine Inorganic materials 0.000 claims 10
- 125000001188 haloalkyl group Chemical group 0.000 claims 10
- 229910052794 bromium Inorganic materials 0.000 claims 9
- 229910052740 iodine Inorganic materials 0.000 claims 9
- 125000005843 halogen group Chemical group 0.000 claims 8
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims 8
- 238000001794 hormone therapy Methods 0.000 claims 8
- 125000004450 alkenylene group Chemical group 0.000 claims 7
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 6
- 125000003282 alkyl amino group Chemical group 0.000 claims 6
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 claims 6
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 6
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 6
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 6
- 125000004663 dialkyl amino group Chemical group 0.000 claims 6
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims 6
- 125000004472 dialkylaminosulfonyl group Chemical group 0.000 claims 6
- 102000015694 estrogen receptors Human genes 0.000 claims 6
- 108010038795 estrogen receptors Proteins 0.000 claims 6
- 125000004438 haloalkoxy group Chemical group 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims 4
- 229940095743 selective estrogen receptor modulator Drugs 0.000 claims 4
- DJXMSZSZEIKLQZ-IRXDYDNUSA-N aderbasib Chemical compound COC(=O)N([C@@H]([C@H](C1)C(=O)NO)C(=O)N2CCN(CC2)C=2C=CC=CC=2)CC21CC2 DJXMSZSZEIKLQZ-IRXDYDNUSA-N 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 230000003054 hormonal effect Effects 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 claims 2
- 239000002677 5-alpha reductase inhibitor Substances 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical group OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 claims 2
- 230000001919 adrenal effect Effects 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 239000003098 androgen Substances 0.000 claims 2
- 239000003936 androgen receptor antagonist Substances 0.000 claims 2
- 230000002280 anti-androgenic effect Effects 0.000 claims 2
- 229940046836 anti-estrogen Drugs 0.000 claims 2
- 230000001833 anti-estrogenic effect Effects 0.000 claims 2
- 239000000051 antiandrogen Substances 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 125000005026 carboxyaryl group Chemical group 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 229940011871 estrogen Drugs 0.000 claims 2
- 239000000262 estrogen Substances 0.000 claims 2
- 239000000328 estrogen antagonist Substances 0.000 claims 2
- 229960002258 fulvestrant Drugs 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 239000000186 progesterone Substances 0.000 claims 2
- 229960003387 progesterone Drugs 0.000 claims 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 2
- 125000003003 spiro group Chemical group 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 125000006832 (C1-C10) alkylene group Chemical group 0.000 claims 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 claims 1
- 102000014654 Aromatase Human genes 0.000 claims 1
- 108010078554 Aromatase Proteins 0.000 claims 1
- 229940122815 Aromatase inhibitor Drugs 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 108700012941 GNRH1 Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
- 229940030486 androgens Drugs 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 claims 1
- 239000003886 aromatase inhibitor Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940044683 chemotherapy drug Drugs 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims 1
- 239000002474 gonadorelin antagonist Substances 0.000 claims 1
- 239000002434 gonadorelin derivative Substances 0.000 claims 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000011591 potassium Chemical group 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 0 *C(BC(*1)(*C2(*)*)*C2(*)N[U][U]*)(C2)C12I Chemical compound *C(BC(*1)(*C2(*)*)*C2(*)N[U][U]*)(C2)C12I 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73891905P | 2005-11-22 | 2005-11-22 | |
| US60/738,919 | 2005-11-22 | ||
| PCT/US2006/045151 WO2007062093A2 (en) | 2005-11-22 | 2006-11-21 | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009516747A JP2009516747A (ja) | 2009-04-23 |
| JP2009516747A5 true JP2009516747A5 (enExample) | 2010-01-14 |
| JP5256042B2 JP5256042B2 (ja) | 2013-08-07 |
Family
ID=37994504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008542425A Active JP5256042B2 (ja) | 2005-11-22 | 2006-11-21 | 癌の処置のための併用療法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8324194B2 (enExample) |
| EP (1) | EP1951242A2 (enExample) |
| JP (1) | JP5256042B2 (enExample) |
| CA (1) | CA2628747C (enExample) |
| WO (1) | WO2007062093A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8088737B2 (en) | 2003-04-04 | 2012-01-03 | Incyte Corporation | Compositions, methods and kits relating to Her-2 cleavage |
| WO2004096139A2 (en) | 2003-04-24 | 2004-11-11 | Incyte Corporation | Aza spiro alkane derivatives as inhibitors of metalloproteases |
| MXPA06004191A (es) | 2003-10-17 | 2007-01-19 | Incyte Corp | Hidroxamatos ciclicos sustituidos en la forma inhibidores de metaloproteinasas de matriz. |
| WO2007016597A2 (en) * | 2005-07-29 | 2007-02-08 | The Regents Of The University Of California | Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy |
| WO2007143600A2 (en) | 2006-06-05 | 2007-12-13 | Incyte Corporation | Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases |
| SG186656A1 (en) | 2007-12-14 | 2013-01-30 | Bristol Myers Squibb Co | Binding molecules to the human ox40 receptor |
| WO2010141543A1 (en) * | 2009-06-02 | 2010-12-09 | Targeted Molecular Diagnostics, Llc | Methods for the detection and quantitation of the p95 component of her2/neu (erbb2) |
| WO2011083391A2 (en) | 2010-01-05 | 2011-07-14 | Pfizer Inc. | Biomarkers for anti-igf-ir cancer therapy |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| ES2620668T3 (es) | 2012-03-02 | 2017-06-29 | Genentech, Inc. | Derivados de amidas y sulfonamidas amido espirocíclicas |
| CN102600073B (zh) * | 2012-03-31 | 2014-01-01 | 莱普德制药有限公司 | 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法 |
| NZ701324A (en) | 2012-05-04 | 2016-09-30 | Pfizer | Prostate-associated antigens and vaccine-based immunotherapy regimens |
| KR20160006168A (ko) | 2013-03-18 | 2016-01-18 | 바이오서오엑스 프로덕스 비.브이. | 인간화 항-cd134(ox40) 항체 및 이의 용도 |
| WO2014169462A1 (zh) * | 2013-04-18 | 2014-10-23 | 西安力邦医药科技有限责任公司 | 具有抗癌活性的7-α-[9-(4,4,5,5,-五氟戊基亚硫酰基)壬基]-雌甾-1,3,5(10)-三烯-3,17β-二醇的酯类衍生物及其制备方法 |
| WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | Anti-cd137 molecules and use thereof |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| WO2021228178A1 (en) | 2020-05-13 | 2021-11-18 | Adagene Ag | Compositions and methods for treating cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0008172D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Therapy |
| BR0113625A (pt) * | 2000-09-08 | 2003-07-22 | Pharmacia Italia Spa | Exemestano como agente de quimioprevenção |
| WO2002072106A2 (en) | 2001-01-26 | 2002-09-19 | Pharmacia Italia Spa | Combined method for treating hormono-dependent disorders with exemestane |
| US8088737B2 (en) * | 2003-04-04 | 2012-01-03 | Incyte Corporation | Compositions, methods and kits relating to Her-2 cleavage |
| WO2004096139A2 (en) * | 2003-04-24 | 2004-11-11 | Incyte Corporation | Aza spiro alkane derivatives as inhibitors of metalloproteases |
| MXPA06004191A (es) | 2003-10-17 | 2007-01-19 | Incyte Corp | Hidroxamatos ciclicos sustituidos en la forma inhibidores de metaloproteinasas de matriz. |
| WO2005117882A2 (en) | 2004-04-20 | 2005-12-15 | Incyte Corporation | Hydroxamic acid derivatives as metalloprotease inhibitors |
| WO2007143600A2 (en) * | 2006-06-05 | 2007-12-13 | Incyte Corporation | Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases |
-
2006
- 2006-11-21 US US11/602,659 patent/US8324194B2/en active Active
- 2006-11-21 CA CA2628747A patent/CA2628747C/en active Active
- 2006-11-21 WO PCT/US2006/045151 patent/WO2007062093A2/en not_active Ceased
- 2006-11-21 JP JP2008542425A patent/JP5256042B2/ja active Active
- 2006-11-21 EP EP06838238A patent/EP1951242A2/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009516747A5 (enExample) | ||
| CA2628747A1 (en) | Combinations of hormone therapy agents and metalloprotease inhibitors for the treatment of cancer | |
| US6291505B1 (en) | Estrogen receptor modulators | |
| US7186838B2 (en) | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | |
| CN101243052B (zh) | 螺旋结构12定位的非甾族抗雄激素物质 | |
| CN104428309B (zh) | 3-取代的雌甾-1,3,5(10),16-四烯衍生物、其制备方法、包含其的药物制剂及其用于制备药物的用途 | |
| JP5595402B2 (ja) | アンドロゲン受容体モジュレーターとしての新規イミダゾリジン化合物 | |
| US20100331333A1 (en) | Imidazo [1,2-B] Pyridazine Compounds | |
| US10344034B2 (en) | Pyrazolopyrimidone or Pyrrolotriazone derivatives, method of preparing same, and pharmaceutical applications thereof | |
| CN101175747A (zh) | 作为选择性雄激素受体调节剂的取代的n-芳基吡咯烷化合物 | |
| EP1581217A1 (en) | Carbonylamino-benzimidazole derivatives as androgen receptor modulators | |
| JP4607860B2 (ja) | 腫瘍阻害作用を有する抗−アンドロゲン性ピロリジン | |
| JP2002522425A (ja) | エストロゲンレセプターモジュレーターとしての置換イソオキサゾール | |
| TW201607943A (zh) | 作為ｅｐ４配體之新穎苯并咪唑衍生物 | |
| CN105873917A (zh) | 含有吡啶基部分的非甾体类抗雄激素和选择性雄激素受体调节剂 | |
| JP2012502975A (ja) | 治療において有用なアミド化合物 | |
| CN102471365B (zh) | 17-羟基-17-五氟乙基雌-4,9(10)-二烯11-乙炔基苯基衍生物、其制备方法及其在治疗病症中的应用 | |
| US20230000876A1 (en) | Treating cancers with a cyclin-dependent kinase inhibitor | |
| Nakagawa et al. | Progesterone receptor antagonists with a 3-phenylquinazoline-2, 4-dione/2-phenylisoquinoline-1, 3-dione skeleton | |
| ES2264032T3 (es) | Derivados de n-fenilamino-1h-imidazol como inhibidores de la aromatasa. | |
| CN110963957B (zh) | N-芳香酰胺类化合物及其制备方法和用途 | |
| HK1223609B (zh) | 含有吡啶基部分的非甾体类抗雄激素和选择性雄激素受体调节剂 | |
| JP2007204371A (ja) | 複素環誘導体 | |
| JP2002543154A (ja) | ２，１−ベンゾイソチアゾリン２，２−ジオキシドおよびプロゲステロン剤を含む避妊薬組成物 | |
| OA12973A (en) | 1-N-phenylamino-1H-imidazole derivatives as aromatase inhibitors. |